Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Opportunistic Screening of Chronic Liver Disease with Deep-Learning-Enhanced Echocardiography

Sahashi Y, Vukadinovic M, Amrollahi F, Trivedi H, Rhee J, Chen J, Cheng S, Ouyang D, Kwan AC. Opportunistic Screening of Chronic Liver Disease with[...]

Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination

Bower JE, Radin A, Ganz PA, Irwin MR, Cole SW, Petersen L, Asher A, Hurvitz SA, Crespi CM. Inflammation and dimensions of fatigue in women[...]

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

Fava A, Wagner CA, Guthridge CJ, Macwana S, DeJager W, Munroe ME, Izmirly P, Belmont HM, Diamond B, Davidson A, Utz PJ, Weisman MH, Carlucci[...]